Dr Amanda Wooding - Deputy Head of Life Sciences
Amanda is Deputy Head of Life Sciences in the technology transfer team at Cambridge Enterprise, developing the Associate team members who work with technologies across the range of life sciences at the University. Amanda works closely with the Seed Funds team, building and supporting early stage companies who are accessing University Technology.
Highlights include the successful incorporation of PredictImmune Limited, a business dedicated to using the power of prognosis to manage treatment options. As with all projects, this involved building long term relationships with academic teams, winning funding, identifying and building a business opportunity, sourcing fledgling company management and carefully managing the interest of all stakeholders throughout.
Other activities have included complex technology portfolio licences in the materials field and raising funding for University initiatives in the translational space. Amanda is currently a Director of PredictImmune Limited and served on the board of Sphere Fluidics Limited for six years.
Previously Amanda worked for Acambis as the UK Director of Business Development where she notably secured a Phase III out licensing agreement with Sanofi Pasteur and managed the sale of a business unit to Crucell. While working for the Wellcome Trust in a forerunner of the Innovations team, she served as the Wellcome Trust observer to the board for three start-up biotechnology companies.
Amanda has a PhD in molecular endocrinology from the University of Cambridge and enjoyed post-doctoral research positions both at Cambridge and in industry. She has seven published academic papers and patent families.
Outside of Cambridge Enterprise, Amanda is a member of the BBSRC Follow on Fund Committee.
Amanda joined Cambridge Enterprise in January 2009 and became Deputy Head of Life Sciences in 2012.